Form 4: Oncology Institute Director Brad Hively Acquires Shares and Warrants in Private Placement

Director Brad Hively purchased shares and warrants of Oncology Institute, Inc. through a private placement.

Summary

• Brad Hively, a director of Oncology Institute, Inc., acquired 9,056 shares of common stock and 4,528 common warrants on March 26, 2025.
• The transaction was part of a private placement where Hively purchased units consisting of two shares of common stock and one common warrant.
• Each unit was priced at $2.2084, with the common stock valued at $1.0417 per share and the common warrant at $0.1250.
• The common warrants have an exercise price of $1.198 and expire on March 26, 2030.
• Hively's beneficial ownership following the transaction is 675,809 shares of common stock and 4,528 common warrants.
• Hively is restricted from exercising the warrants if it would result in him beneficially owning more than 4.99% of the company's outstanding common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The director's purchase could be seen as a positive signal, but it's not overwhelmingly significant.

Positives

• Insider buying can sometimes be seen as a positive signal, indicating confidence in the company's future prospects.

Risks

• The warrant exercise restriction could limit Hively's ability to fully capitalize on potential stock appreciation.

Industry Context

Insider transactions are routinely monitored and reported to the SEC. This transaction is a routine disclosure of a director's investment in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Oncology Institute, Director, Brad Hively, Private Placement, Common Stock, Common Warrant, Beneficial Ownership, Insider Trading